AbCellera Biologics Inc.
ABCL
$4.39
$0.092.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.88M | 23.12M | 28.83M | 32.96M | 33.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.88M | 23.12M | 28.83M | 32.96M | 33.06M |
| Cost of Revenue | 168.75M | 170.47M | 167.26M | 169.81M | 166.75M |
| Gross Profit | -135.88M | -147.35M | -138.43M | -136.84M | -133.70M |
| SG&A Expenses | 82.50M | 83.84M | 85.49M | 85.40M | 80.96M |
| Depreciation & Amortization | 28.29M | 59.34M | 58.85M | 85.82M | 54.64M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 279.54M | 313.65M | 311.60M | 341.03M | 302.35M |
| Operating Income | -246.66M | -290.53M | -282.77M | -308.06M | -269.29M |
| Income Before Tax | -198.79M | -210.63M | -200.40M | -202.17M | -178.81M |
| Income Tax Expenses | -33.12M | -42.76M | -37.54M | -26.37M | -25.51M |
| Earnings from Continuing Operations | -165.67 | -167.87 | -162.86 | -175.80 | -153.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.67M | -167.87M | -162.86M | -175.80M | -153.30M |
| EBIT | -246.66M | -290.53M | -282.77M | -308.06M | -269.29M |
| EBITDA | -184.23M | -197.05M | -189.77M | -222.24M | -214.65M |
| EPS Basic | -0.56 | -0.57 | -0.55 | -0.60 | -0.53 |
| Normalized Basic EPS | -0.42 | -0.45 | -0.43 | -0.48 | -0.40 |
| EPS Diluted | -0.56 | -0.57 | -0.56 | -0.61 | -0.54 |
| Normalized Diluted EPS | -0.42 | -0.45 | -0.43 | -0.48 | -0.40 |
| Average Basic Shares Outstanding | 1.19B | 1.18B | 1.18B | 1.17B | 1.17B |
| Average Diluted Shares Outstanding | 1.19B | 1.18B | 1.18B | 1.17B | 1.17B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |